National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Pembrolizumab (Keytruda®) as monotherapy is indicated for the adjuvant treatment of adults with Stage III melanoma and lymph node involvement who have undergone complete resection.

NCPE Assessment Process Complete
Rapid review commissioned 19/11/2018
Rapid review completed 07/12/2018
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by the HSE 19/12/2018
Pre-submission consultation with Applicant 14/01/2019
Submission received from Applicant 16/07/2019
Current status Submission received from applicant